Luminor Medical Announces Listing on the Canadian Securities Exchange

Luminor Medical Technologies Inc. (the “Company”)  (TSXV:LMT) (CSE:LMT) announced today that the Canadian Securities Exchange (CSE) has approved the Company’s application to list its common shares on the CSE. Effective December 1, 2017, the Company’s shares will commence trading on the CSE under the symbol LMT. The Company has also applied for a voluntary delisting of its common shares from the TSX Venture Exchange (“TSXV”). The voluntary delisting is subject to the approval of the TSXV.
The Company’s move from the TSXV to the CSE follows the acquisition of Jamaica BLU Ltd. (“J-BLU”). J-BLU holds the exclusive Canadian licence of all current and future cannabis commercial products developed by Rise Research Inc. (“RISE”). RISE’s cannabis commercial products are based on a patent pending formula, currently filed with the U.S. Patent and Trademark Office, to create precise cannabis-based formulations that may produce specifically targeted effects for various ailments including diabetes. Currently, RISE’s portfolio consists of cannabis-based formulations which support patients with low libido called Jamaica blū and Jamaica pnk.
The move to the CSE will give the Company, and specifically J-BLU, more opportunity to acquire licences on products outside of Canada.
About Luminor Medical Technologies
Luminor Medical Technologies operates through its two wholly owned subsidiaries – Scout Assessment Corp. and Jamaica BLU Limited. Scout Assessment Corp.’s key product is the Scout DS®, a device that has been regulatory cleared in certain markets both as a non-invasive clinical tool to assist in the identification of both prediabetes and type 2 diabetes. Jamaica BLU Limited holds the exclusive Canadian licence of all current and future cannabis commercial products developed by Rise Research Inc. Currently, Rise Research’s portfolio consists of cannabis-based formulations which support patients with low libido called Jamaica blū and Jamaica pnk.
For more information, please contact:
Mark Komonoski
Communication Director
mark@komonoski.com
877-255-8483
403-470-8384
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.
Click here to connect with Luminor Medical Technologies Inc. (TSXV:LMT) to receive an Investor Presentation

Source: www.newsfilecorp.com